JUDY WOODRUFF: The prices of healthcare are
a pocketbook issue for most Americans, and also rising medication costs, a vital component of that. People in the U.S. invest a lot more on prescription
drugs than in any various other nation, regarding $1,200 a year each. Insurance providers and the federal government pay the largest
share. But it'' s costing consumers even more cash in costs
and out of pocket. Rage has been building over affordability
as well as specialty drugs that cost tens of countless dollars. That was the backdrop for a much-anticipated
Us senate hearing today including the drug manufacturers. John Yang has that report. JOHN YANG: It has actually been decades considering that this
several leaders of the leading drug makers have actually encountered legislators under oath. Senators in both celebrations lashed out at their
profit margins as well as pressed them to clarify why medication rates keep rising. SEN. RON WYDEN (D), Oregon: All of you that are
below today are below because the way you have actually been doing business is unacceptable. JOHN YANG: Finance Board Chairman Chuck
Grassley established the tone, tearing right into the execs of 7 pharmaceutical titans for shirking
responsibility.SEN.
CHARLES GRASSLEY (R), Iowa: One more yes-or-no
concern: When you'' re company costs its medicines, do you take into account the fact that a key
player is the federal government? Let'' s begin with AbbVie. RICHARD GONZALEZ, CHIEF EXECUTIVE OFFICER, AbbVie Laboratories:
We evaluate all the networks when we make decisions on rate as well as affordability. SEN. CHARLES GRASSLEY: So, that certainly would
include the federal government? AstraZeneca. PASCAL SORIOT, CEO, AstraZeneca: Yes, we do. SEN. CHARLES GRASSLEY: OK, Bristol-Myers. GUY: Yes, Senator.SEN.
CHARLES GRASSLEY: Johnson & & Johnson. FEMALE: Yes. SEN. CHARLES GRASSLEY: Merck. KENNETH C. FRAZIER, CEO, Merck: Yes. SEN. CHARLES GRASSLEY: Pfizer. MAN: Absolutely. SEN. CHARLES GRASSLEY: And Sanofi. MALE: Yes. JOHN YANG: The execs all stated they were
going to do more to make certain individuals might pay for the drugs they need, yet used couple of
details. They claimed middlemen were responsible, as well as that
creating brand-new medicines calls for billions of dollars in research study. PASCAL SORIOT: Our company is committed to
scientific research and also development. And in 2018, we invested nearly $6 billion
in study and development. KENNETH C. FRAZIER: We'' re proud to have actually released
70,000 dosages of our experimental Ebola injection in the Congo.JENNIFER TAUBERT, Executive Vice Head Of State, Janssen: We concentrate on uncovering and also establishing transformational medicines for several of the world ' s most difficult conditions, including several myeloma, prostate cancer cells, HIV, schizophrenia, and Crohn'' s disease, to name a few. Janssen invested $8.4 billion in research and also growth in 2014 in the look for clinical advancements. JOHN YANG: Democrat Maria Cantwell of Washington state pressed the execs to acknowledge that the government can aid bring prices down. SEN. MARIA CANTWELL (D), Washington: I'' m asking a really basic question, like the VA'' s capacity to negotiate on medication prices.Do you believe that states having that same capability drives down rate? KENNETH C. FRAZIER: I would certainly claim that the VA. would certainly obtain a reduced price as well as the states would get a reduced rate if you ' re willing to go. into an atmosphere where that might
be enforced by the states. SEN. MARIA CANTWELL: Or the federal government? JOHN YANG: The hearing comes as President. Trump targets medication costs.He ' s recommended finishing Medicare and Medicaid.
rebates to intermediaries and also cutting the rate Medicare pays for some medications. DONALD TRUMP, President of the United States:. At long last the drug companies in international countries will be held liable for how. they set up the system against American customers. JOHN YANG: Today, senators endangered legislative. action. Several zeroed in on Richard Gonzalez, CHIEF EXECUTIVE OFFICER.
of AbbVie, the maker of Humira. It ' s the successful medication on the planet used. for rheumatoid arthritis and also various other diseases, yearly sales virtually$ 20 billion. Over the last 6 years, the drug ' s cost. has increased to$ 38,000 a year. More than 100 AbbVie licenses and also manage. other medication manufacturers indicate that lower-price competitors will not hit the united state market before 2023. SEN. JOHN CORNYN( R), Texas: The number of patents? I ' m sorry.RICHARD GONZALEZ: One hundred and thirty-six. SEN. JOHN CORNYN: One hundred and also thirty-six patents. on one drug? RICHARD GONZALEZ: Yet, well, bear in mind, Humira. is like nine various medications or 10 various medications. SEN. JOHN CORNYN: I believed you said to Legislator.
Stabenow it was the very same particle. RICHARD GONZALEZ: It is the same particle,. however it deals with different condition, as well as
if you check out that license profile … (CROSSTALK) SEN. JOHN CORNYN: So, you use the same particle. to treat various conditions, you can get a license on that particular treatment? RICHARD GONZALEZ: Certainly.SEN. JOHN CORNYN: Mr. Chairman, I understand
this subject. is the topic of– or within the jurisdiction of the Financing Board, yet those of us.
like you as well as me that are additionally on the Judiciary Committee that
has territory over the patent. system, I think this is a location that we need to look in via our Judiciary Board. authority. JOHN YANG: Senator Ron Wyden of Oregon, the.
panel ' s top Democrat, asked Gonzalez if his compensation, which was$ 22 million in 2017,. is connected to Humira sales.
SEN. RON WYDEN: Would certainly you make a smaller bonus offer. if you dropped the cost of Humira? RICHARD GONZALEZ: Humira was one aspect of. a collection of financial aspects that were evaluated as component
of my compensation. It ' s clearly a really substantial item. for us, so it ' s clear that it would be component of that evaluation. SEN. RON WYDEN: I would like that in composing within. 10 days.JOHN YANG: Some Chief Executive Officers, like Merck ' s Ken Frazier,. stated they were eager to do points like getting rid of discounts that help protect their market share,.
yet, overall,
firms protected their methods.'KENNETH C. FRAZIER: No one company can unilaterally. reduced sticker price without encountering monetary as well as running drawbacks.
JOHN YANG: By the hearing ' s end, Wyden and also. other legislators said they were much from completely satisfied.
SEN. RON WYDEN: I have actually heard a lot of delighted talk. this early morning. JOHN YANG: Today ' s hearing included more bipartisan. objection than in the past, yet it is much from clear what action Congress will take. as drug costs proceed to rise.For the “PBS NewsHour,” I ' m John Yang.
